I. To compare quality of life in patients with advanced ovarian cancer treated with neoadjuvant chemotherapy (NAC) followed by cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) versus NAC followed by CRS and postoperative intraperitoneal (IP) chemotherapy at 6 weeks post-treatment.